Choosing ImmunotherapyVideo Categories: 2018 AONN Midyear, Immunotherapy, and Video Library
Dr Morganna Freeman outlines some of the criteria used in deciding which patients will most benefit from immunotherapy.
Drs. Goeffrey Oxnard and Lauren Ritterhouse discuss the need for validation and standardization of Tumor Mutational Burden to make it a robust biomarker, in conjunction with PD-L1, in selecting immunotherapy for their lung cancer patients.
In this second clinical commentary entitled, Management of Patients with Basal Cell Carcinoma not Eligible for Surgery or Radiation, Joel Claveau, MD, CSPQ, FRCPC; Dirk Schadendorf, MD; Nicole Basset-Seguin, MD, PhD and Aleksandar Sekulic, MD, PhD discuss the need for new treatment options in the care of basal cell carcinoma [ Read More ]